Vitamin D in AKI Version 1
Research type
Research Study
Full title
Vitamin D levels in critically ill patients with acute kidney injury (VID-AKI)
IRAS ID
196968
Contact name
Marlies Ostermann
Contact email
Sponsor organisation
Guy's & St Thomas' Hospital
Duration of Study in the UK
3 years, 0 months, 1 days
Research summary
Vitamin D has an important role in the regulation of bone metabolism and various infectious, cardiovascular and respiratory diseases. The majority of vitamin D is produced through the direct action of sunlight in the skin and some stems from dietary sources. Vitamin D has to undergo an activation process within the kidneys to be active in the body.
It has been shown that vitamin D deficiency is relatively common in patients who are critically ill and associated with worse outcomes. It is also well known that patients with chronic end-stage renal failure develop Vitamin D deficiency and should routinely receive Vitamin D supplements to prevent fractures and cardiovascular problems (NICE recommendation). To date, it is not known whether this also applies to patients with acute kidney failure, also known as acute kidney injury (AKI).
Our hypothesis is that critically ill patients with AKI have significantly lower Vitamin D levels than critically ill patients without AKI.
We plan to measure Vitamin D levels and related hormones in 63 critically ill patients with AKI and 63 critcally ill patients without AKI over a period of 5 days. In addition, we plan to do an additional measurement on day of discharge from the Intensive Care Unit. To understand better how Vitamin D is regulated in AKI, we plan to measure different types of Vitamin D (Vitamin D2 and D3), parathyroid hormone (PTH), Fibroblast growth factor 23 and Vitamin D Binding Protein and perform a gene expression analysis of Vitamin D.
All blood samples will be frozen until batch analysis in 2 different laboratories within our institution. We will also collect demographic data, routine laboratory results, severity of illness scores and outcome data.
There will be no change in clinical management.
The results will inform us whether to perform an intervention study in future.
REC name
London - Camberwell St Giles Research Ethics Committee
REC reference
16/LO/0466
Date of REC Opinion
30 Mar 2016
REC opinion
Favourable Opinion